Niagen Bioscience (NAGE) Common Equity (2011 - 2026)

Niagen Bioscience (NAGE) has 15 years of Common Equity data on file, last reported at $82.3 million in Q1 2026.

• Common Equity for Q1 2026 came in at $82.3 million, up 48.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.3 million (up 48.76% YoY), and the FY2025 annual result was $76.5 million, up 66.04% from the prior year.
• Common Equity rose to $82.3 million in Q1 2026 per NAGE's latest filing, from $76.5 million in the prior quarter.
• Over five years, Common Equity peaked at $82.3 million in Q1 2026 and troughed at $20.8 million in Q2 2022.
• A 5-year average of $41.0 million and a median of $29.0 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity slumped 50.7% in 2022, then jumped 108.98% in 2025.
• A 5-year view of Common Equity shows it stood at $28.7 million in 2022, then dropped by 0.75% to $28.5 million in 2023, then jumped by 61.98% to $46.1 million in 2024, then jumped by 66.04% to $76.5 million in 2025, then advanced by 7.57% to $82.3 million in 2026.
• Business Quant data shows NAGE's Common Equity at $82.3 million in Q1 2026, $76.5 million in Q4 2025, and $70.7 million in Q3 2025.